斯巴森坦：首次批准。
Sparsentan: First Approval.
机构信息
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
出版信息
Drugs. 2023 Apr;83(6):563-568. doi: 10.1007/s40265-023-01864-x.
Sparsentan (FILSPARI™) is an oral, dual endothelin angiotensin receptor antagonist that is being developed by Travere Therapeutics for the treatment of immunoglobulin A (IgA) nephropathy and focal segmental glomerulosclerosis (FSGS). In February 2023, sparsentan received accelerated approval in the USA for reducing proteinuria in adults with primary IgA nephropathy who are at risk of rapid disease progression. This article summarizes the milestones in the development of sparsentan leading to this first approval for IgA nephropathy.
斯巴森坦（FILSPARI™）是一种口服的双重内皮素血管紧张素受体拮抗剂，由 Travere Therapeutics 公司开发，用于治疗免疫球蛋白 A（IgA）肾病和局灶节段性肾小球硬化症（FSGS）。2023 年 2 月，斯巴森坦在美国获得加速批准，用于降低有快速疾病进展风险的原发性 IgA 肾病成人患者的蛋白尿。本文总结了斯巴森坦开发过程中的重要里程碑，最终使其获得 IgA 肾病的首次批准。
Zotero 插件